Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2

Conditions

Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignancies 1

Interventions

pembrolizumab 221Carboplatin 214Cisplatin 202Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 113Cyclophosphamide 101Pemetrexed 100Dexamethasone 100Specimen Handling 98Oxaliplatin 96Magnetic Resonance Spectroscopy 96Radiotherapy 92Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 67durvalumab 65Lenalidomide 64atezolizumab 61Radiation 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × sitravatinib × 1 year × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

NCT03906071 2025-10-21

SAPPHIRE

Mirati Therapeutics Inc.

Phase 3 Completed
577 enrolled 22 charts
Thoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04921358 2025-06-29

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

BeiGene

Phase 3 Terminated
377 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡